SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie ABBV shares are down 12.4%. In a statement ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...

Bristol-Myers Squibb Up Over 11%, on Pace for Largest Percent Increase Since March 2000 — Data Talk Bristol-Myers Squibb Company (BMY) is currently at $60.49, up $6.35 or 11.73% --Would be highest ...

AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical company's shares ...

Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Meanwhile, shares of Bristol Myers Squibb, makers of recently approved schizophrenia treatment Cobenfy, soared 12%. Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Bristol Myers Squibb’s robust cardiovascular portfolio and significant upcoming data presentations at the AHA meeting are positioning the company as a key player in the fight against cardiovascular ...